Table 3 Patients characteristics (SD—standard deviation, AC—adenocarcinoma, NSCLC NOS—non-small cell lung cancer not otherwise specified, CTH—chemotherapy).
From: Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
Patients with ROS1 rearrangement | Patients with ALK rearrangement | Patients with EGFR gene mutations | Patients with MET skipping mutation | Patients with PD-L1 expression on ≥ 50% TC | Patients without detected alterations | |
|---|---|---|---|---|---|---|
Number | 9 | 23 | 10 | 5 | 23 | 25 |
Age (median ± SD) | 66 ± 6 years | 69.5 ± 3.5 years | 67 ± 10.3 years | 69 ± 8.5 years | 58.5 ± 4.5 years | 65 ± 8.1 years |
Gender (number) | Female (4) | Female (11) | Female (7) | Female (3) | Female (10) | Female (7) |
Male (5) | Male (12) | Male (3) | Male (2) | Male (13) | Male (18) | |
Smoking status | Non-smokers (5) | Non-smokers (13) | Non-smokers (8) | Non-smokers (2) | Non-smokers (4) | Non-smokers (5) |
Smokers (4) | Smokers (10) | Smokers (2) | Smokers (3) | Smokers (19) | Smokers (20) | |
Pathomorfological diagnosis (number) | AC (9) | AC (19) | AC (10) | AC (4) | AC (20) | AC (25) |
NSCLC NOS (4) | NSCLC NOS (1) | NSCLC NOS (3) | ||||
1st line treatment (number) | Krizotinib (3) | Krizotinib (7) | Gefitinib (1) | CTH (5) | Pembrolizumab (17) | CTH (30) |
CTH (6) | CTH (16) | Erlotinib (5) | CTH (6) | |||
Afatinib (4) |
